Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment symbols : AXSM save search
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
Published: 2024-04-01 (Crawled : 11:00) - globenewswire.com
AXSM | $65.81 -5.6% -5.93% 830K
|
Health Technology
|
| O: 0.32%
H: 0.0%
C: -3.52%
treatment trial therapeutics solriamfetol
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
Published: 2024-03-19 (Crawled : 11:00) - globenewswire.com
AXSM | $65.81 -5.6% -5.93% 830K
|
Health Technology
|
| O: 0.84%
H: 5.95%
C: 5.09%
treatment trial therapeutics solriamfetol
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
Published: 2023-07-07 (Crawled : 11:00) - globenewswire.com
AXSM | $65.81 -5.6% -5.93% 830K
|
Health Technology
|
| O: 0.69%
H: 0.07%
C: -2.31%
treatment trial therapeutics solriamfetol
Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
Published: 2022-10-20 (Crawled : 12:00) - biospace.com/
AXSM | $65.81 -5.6% -5.93% 830K
|
Health Technology
|
| O: -0.71%
H: 2.82%
C: -1.14%
treatment therapeutics major depressive disorder
Axsome Therapeutics Announces FDA Approval of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
Published: 2022-08-19 (Crawled : 11:00) - globenewswire.com
AXSM | $65.81 -5.6% -5.93% 830K
|
Health Technology
|
| O: 22.3%
H: 17.77%
C: 14.76%
treatment fda approval therapeutics major depressive disorder
Axsome Therapeutics Receives FDA Complete Response Letter for New Drug Application for AXS-07 for the Acute Treatment of Migraine
Published: 2022-05-02 (Crawled : 12:20) - biospace.com/
AXSM | $65.81 -5.6% -5.93% 830K
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
axs-07 treatment fda drug application therapeutics response migraine
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of Migraine
Published: 2021-09-14 (Crawled : 12:00) - biospace.com/
AXSM | $65.81 -5.6% -5.93% 830K
|
Health Technology
|
| O: 3.53%
H: 1.41%
C: -8.01%
new drug treatment fda fda acceptance migraine drug application
Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive Disorder
Published: 2021-08-23 (Crawled : 11:00) - globenewswire.com
AXSM | $65.81 -5.6% -5.93% 830K
|
Health Technology
|
| O: 26.13%
H: 1.63%
C: -1.63%
new drug treatment drug depression application major depressive disorder
Axsome Therapeutics Announces AXS-05 Achieves Primary and Key Secondary Endpoints in the MERIT Phase 2 Trial in Treatment Resistant Depression
Published: 2021-08-09 (Crawled : 12:00) - biospace.com/
AXSM | $65.81 -5.6% -5.93% 830K
|
Health Technology
|
| O: -34.96%
H: 6.06%
C: -17.06%
treatment phase 2 depression trial
Axsome Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major Depressive Disorder
Published: 2021-04-26 (Crawled : 11:00) - globenewswire.com
AXSM | $65.81 -5.6% -5.93% 830K
|
Health Technology
|
| O: 10.84%
H: 4.9%
C: 0.14%
new drug treatment fda fda acceptance drug depression major depressive disorder
Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine
Published: 2020-12-31 (Crawled : 11:03) - globenewswire.com
AXSM | $65.81 -5.6% -5.93% 830K
|
Health Technology
|
| O: 1.25%
H: 0.51%
C: -3.36%
positive phase 3 results trial treatment
Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression
Published: 2020-12-02 (Crawled : 11:01) - globenewswire.com
AXSM | $65.81 -5.6% -5.93% 830K
|
Health Technology
|
| O: 0.66%
H: 3.28%
C: 2.84%
positive results depression positive results trial treatment
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.